Literature DB >> 9459591

Quantitative determinations of the steady state transcript levels of hexokinase isozymes and glucose transporter isoforms in normal rat tissues and the malignant tumor cell line AH130.

Y Shinohara1, K Yamamoto, K Inoo, N Yamazaki, H Terada.   

Abstract

The steady state transcript levels of the four hexokinase (HK) isozymes and four glucose transporter (GLUT) isoforms were determined quantitatively by Northern analysis of RNA samples from rat tissues using synthetic fragments of the RNAs encoding the HK isozymes and GLUT isoforms. Results showed that the levels of HK isozyme transcripts were low in rat tissues, the level of that most highly expressed, the type I isozyme (HKI), in the brain being 0.025% of the total poly(A)+ RNA. A good correlation was found between the reported HK activities and the total amounts of transcripts encoding all HK isozymes in various tissues, showing that the HK activities in tissues can be estimated from the total amount of transcripts encoding HK isozymes. The proposed associated expressions of HK isozymes and GLUT isoforms in particular tissues were confirmed at their transcript levels. The steady state transcript levels of type II HK and the type 1 GLUT isoform in the malignant tumor cell line AH130 were also determined quantitatively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459591     DOI: 10.1016/s0005-2736(97)00189-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II.

Authors:  Lei Gong; Zhuqingqing Cui; Pengcheng Chen; Hui Han; Jirun Peng; Xisheng Leng
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

2.  mTORC2 sustains thermogenesis via Akt-induced glucose uptake and glycolysis in brown adipose tissue.

Authors:  Verena Albert; Kristoffer Svensson; Mitsugu Shimobayashi; Marco Colombi; Sergio Muñoz; Veronica Jimenez; Christoph Handschin; Fatima Bosch; Michael N Hall
Journal:  EMBO Mol Med       Date:  2016-03-01       Impact factor: 12.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.